BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 35503762)

  • 1. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression.
    Koyama K; Ishikawa H; Abe M; Shiose Y; Ueno S; Qiu Y; Nakamaru K; Murakami M
    PLoS One; 2022; 17(5):e0267027. PubMed ID: 35503762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study.
    Oliveira M; Falato C; Cejalvo JM; Vila MM; Tolosa P; Salvador-Bofill FJ; Cruz J; Arumi M; Luna AM; Guerra JA; Vidal M; Martínez-Sáez O; Paré L; González-Farré B; Sanfeliu E; Ciruelos E; Espinosa-Bravo M; Pernas S; Izarzugaza Y; Esker S; Fan PD; Parul P; Santhanagopal A; Sellami D; Villacampa G; Ferrero-Cafiero JM; Pascual T; Prat A
    Ann Oncol; 2023 Aug; 34(8):670-680. PubMed ID: 37211044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial.
    Krop IE; Masuda N; Mukohara T; Takahashi S; Nakayama T; Inoue K; Iwata H; Yamamoto Y; Alvarez RH; Toyama T; Takahashi M; Osaki A; Saji S; Sagara Y; O'Shaughnessy J; Ohwada S; Koyama K; Inoue T; Li L; Patel P; Mostillo J; Tanaka Y; Sternberg DW; Sellami D; Yonemori K
    J Clin Oncol; 2023 Dec; 41(36):5550-5560. PubMed ID: 37801674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors.
    Lu Y; Shimizu S; Sawamura R; Tajima N; He L; Lee M; Abutarif M; Shi R
    J Clin Pharmacol; 2023 Jan; 63(1):77-90. PubMed ID: 36053771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
    Yu HA; Baik C; Kim DW; Johnson ML; Hayashi H; Nishio M; Yang JC; Su WC; Gold KA; Koczywas M; Smit EF; Steuer CE; Felip E; Murakami H; Kim SW; Su X; Sato S; Fan PD; Fujimura M; Tanaka Y; Patel P; Sternberg DW; Sellami D; Jänne PA
    Ann Oncol; 2024 May; 35(5):437-447. PubMed ID: 38369013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic
    Yu HA; Yang JC; Hayashi H; Goto Y; Felip E; Reck M; Vigliotti M; Dong Q; Cantero F; Fan PD; Kanai M; Sternberg DW; Jänne PA
    Future Oncol; 2023 Jun; 19(19):1319-1329. PubMed ID: 37212796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
    Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
    Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer.
    Koganemaru S; Kuboki Y; Koga Y; Kojima T; Yamauchi M; Maeda N; Kagari T; Hirotani K; Yasunaga M; Matsumura Y; Doi T
    Mol Cancer Ther; 2019 Nov; 18(11):2043-2050. PubMed ID: 31395690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan.
    Ali A; Graff SL
    Curr Oncol Rep; 2024 Jan; 26(1):1-9. PubMed ID: 38091201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
    Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
    Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced
    Mok T; Jänne PA; Nishio M; Novello S; Reck M; Steuer C; Wu YL; Fougeray R; Fan PD; Meng J; Sternberg DW; Esker S; Yu HA
    Future Oncol; 2024 May; 20(15):969-980. PubMed ID: 38095056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
    Bartsch R
    Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
    Indini A; Rijavec E; Grossi F
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
    Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
    Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
    Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
    Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells.
    Nakajima S; Mimura K; Matsumoto T; Thar Min AK; Ito M; Nakano H; Neupane P; Kanke Y; Okayama H; Saito M; Momma T; Watanabe Y; Hanayama H; Hayase S; Saze Z; Kono K
    Sci Rep; 2021 Aug; 11(1):16891. PubMed ID: 34413454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer.
    Shimomura A; Takano T; Takahashi S; Sagara Y; Watanabe J; Tokunaga E; Shinkai T; Kamio T; Kikumori K; Kamiyama E; Fujisaki Y; Saotome D; Yamashita T
    Clin Pharmacol Ther; 2023 Jan; 113(1):160-169. PubMed ID: 36164935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.